Timing clarification: Veralto plans to publish its Q2 results after the market closes today, Tuesday, July 28, 2026. The earnings call is tomorrow, Wednesday, July 29, at 7:30 a.m. ET. (investors.veralto.com)
| Metric | Q2 2026 expectation | Q2 2025 actual |
|---|---|---|
| Revenue | ~$1.45 billion consensus | $1.371 billion |
| Core sales growth | 3%–4% company guidance | 4.8% |
| Adjusted operating margin | ~23.5% company guidance | 23.7% |
| Adjusted EPS | $1.00–$1.01 consensus | $0.93 |
| Company EPS guidance | $0.96–$1.00 | — |
Published estimates cluster around $1.00–$1.01 of adjusted EPS and approximately $1.45 billion of revenue. The revenue estimate implies roughly 6% reported growth, consistent with Veralto’s model of 5.5%–6.5% total sales growth, including acquisitions and currency. (benzinga.com)
The key issue is not whether Veralto can post a small EPS beat. Consensus is already at or just above the top of management’s $0.96–$1.00 guidance, while the full-year consensus of approximately $4.24 sits at the midpoint of the existing $4.20–$4.28 range. (barchart.com)
For the report to be meaningfully positive, investors will probably want some combination of:
A result merely in line with guidance, accompanied by an unchanged outlook, may not be enough. At a share price around the mid-$90s, VLTO trades at roughly 22 times the $4.24 full-year consensus—reasonable for its recurring-revenue and cash-flow profile, but not a valuation that makes execution misses easy to overlook. (barchart.com)
Q1’s consolidated 1.9% core growth masked a sharp segment divergence:
Water Quality benefited from healthy demand and pricing, while PQI’s performance was held back by packaging and color-related businesses. Management nevertheless said core growth should accelerate sequentially through the year, with second-half margins also improving. (investors.veralto.com)
That makes Q2 the first real test of the acceleration thesis. Investors should focus on:
A modest consolidated beat driven entirely by Water Quality, currency and acquisitions would be lower quality than a result showing genuine improvement in PQI.
Water Quality entered Q2 with the stronger operating trajectory. Q1 sales rose 10.1%, including 3.8% core growth and contributions from the In-Situ acquisition. The segment’s adjusted margin expanded slightly despite acquisition-related dilution. (investors.veralto.com)
The primary items to monitor are:
Veralto also acquired India-based Alfaa UV on July 21. The transaction occurred after the quarter, so it should not affect Q2 results, but management may discuss its potential to expand Trojan Technologies in India and elsewhere in Asia-Pacific. (investors.veralto.com)
Management guided to approximately 23.5% adjusted operating margin, essentially flat with last year. Its Q2 model assumed roughly 25 basis points of dilution from In-Situ and approximately $25 million–$30 million of net interest expense. (investors.veralto.com)
Potential positives include:
Potential offsets include:
A margin above 23.5% alongside 4%-plus core growth would be a constructive sign. Conversely, an EPS beat produced mainly through tax, share count or other below-the-line items would carry less weight.
Existing 2026 guidance calls for:
Following $1.07 of adjusted EPS in Q1 and roughly $1.00 expected in Q2, the midpoint of full-year guidance implies about $2.17 across the second half, or approximately $1.09 per quarter on average. That requires further earnings acceleration.
The most bullish outcome would be an increase in the EPS range, supported by stronger operating assumptions rather than only buybacks or taxes. An unchanged range can still be acceptable if management raises the lower end of core growth or expresses greater confidence in second-half PQI recovery. A reduction in margin or cash-flow expectations would be the clearest negative signal.
Veralto initiated a cost-optimization program expected to produce $65 million–$75 million of annual run-rate savings by 2028, against an estimated $85 million–$105 million GAAP charge. Management expects approximately half of the benefit in 2027 and the full benefit in 2028, with no meaningful savings embedded in 2026 guidance. (investors.veralto.com)
Investors should listen for:
Veralto entered the year aggressively: it spent approximately $622 million on In-Situ and GlobalVision and repurchased $300 million of stock. It subsequently raised approximately $721 million of net proceeds through the 2032 notes offering. (investors.veralto.com)
Questions for management include:
Further acquisitions could extend the growth runway, but investors should watch leverage, interest expense and integration complexity.
| Scenario | What it likely looks like |
|---|---|
| Bullish | Core growth above 4%; PQI returns to growth; margin exceeds 23.5%; EPS beats $1.00–$1.01; full-year EPS or core-growth guidance rises. |
| Base case | Core growth within 3%–4%; EPS around $1.00; margin near 23.5%; full-year guidance reiterated or modestly narrowed. |
| Bearish | Core growth below 3%; PQI remains meaningfully negative; margin misses; management becomes less confident in second-half acceleration or trims guidance. |
Veralto’s defensive end markets, roughly 60% recurring sales mix and strong cash generation remain attractive. But this report needs to demonstrate that Q1’s 1.9% core growth was a temporary low point rather than the beginning of a softer growth phase. (investors.veralto.com)
The two numbers that matter most are PQI core growth and the updated full-year EPS range. A routine EPS beat accompanied by continued PQI weakness and unchanged guidance would be less compelling. A credible PQI inflection, solid margin execution and a guidance increase would validate the company’s acceleration thesis and provide the strongest positive catalyst.